Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance

Bristol-Myers Squibb CoTrade
iShares 1 3 Year Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.95 (market cap $129.94B), while iShares 1 3 Year Treasury Bond ETF trades at $81.93. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while iShares 1 3 Year Treasury Bond ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

BMYSHY
Market Cap
$129.94B
Sector
HealthFixed Income
52-Week High
$65.89$83.18
52-Week Low
$42.60$81.77
Enterprise Value
$163.92B
Dividend Yield
3.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.

BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.

iShares 1 3 Year Treasury Bond ETF

SHY (iShares 1-3 Year Treasury Bond ETF) trades at $81.94 with minimal daily movement (+0.1%). The technical picture shows bearish momentum with moving averages signaling caution, though oscillators remain neutral. Recent institutional activity indicates growing interest, with Barry Investment Advisors increasing their position by 48.1% in Q2 2026. Treasury yield fluctuations and inflation data remain key drivers for this short-term bond ETF.

Outlook remains tied to Federal Reserve policy and inflation trends. The ETF offers stability with regular dividends but faces headwinds from rising yields. Investment opportunity lies in capital preservation during market volatility, though rising rates could pressure short-term bond prices. Key risks include interest rate sensitivity and macroeconomic policy shifts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About iShares 1 3 Year Treasury Bond ETF

SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.

Read more on SHY